# Alemtuzumab Use (MabCampath®) in Hematopoietic Transplant of Unrelated Donor With Reduced Intensity Conditioning

> **NCT00781781** · PHASE2 · TERMINATED · sponsor: **CABYC** · enrollment: 34 (actual)

## Conditions studied

- Graft Versus Host Disease

## Interventions

- **DRUG:** Alemtuzumab

## Key facts

- **NCT ID:** NCT00781781
- **Lead sponsor:** CABYC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-07
- **Primary completion:** 2008-08
- **Final completion:** 2011-12
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** Inability to recruit the number of patients established in the study protocol (34 of 40)
- **Last updated:** 2015-02-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00781781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00781781, "Alemtuzumab Use (MabCampath®) in Hematopoietic Transplant of Unrelated Donor With Reduced Intensity Conditioning". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00781781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*